How is desmopressin (DDAVP) used in the treatment of von Willebrand disease (vWD) type 2?

Updated: Dec 30, 2019
  • Author: Eleanor S Pollak, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Responses to DDAVP are variable in patients with type 2 disease; some patients respond while others should receive vWF concentrates. [28] United Kingdom guidelines recommend performing a trial infusion of DDAVP in patients with type 2A, 2M, and 2N vWD and measuring vWF antigen, vWF activity, and FVIII at baseline, 30–60 min, and 4–6 h. [3]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!